NPM1 exon 5 mutations in acute myeloid leukemia: Implications in diagnosis and minimal residual monitoring

被引：2
|
作者：
Wang, Peng [1 ]
Segal, Jeremy [1 ]
Drazer, Michael W. [2 ]
Venkataraman, Girish [1 ]
Arber, Daniel A. [1 ]
Gurbuxani, Sandeep [1 ]
机构：
[1] Univ Chicago, Dept Pathol, MC3083,5841 S Maryland Ave MC0008,5841 S Maryland, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Med, Chicago, IL USA
来源：
EJHAEM | 2022年 / 3卷 / 03期
关键词：
HIGH-DOSE CYTARABINE; AML;
D O I：
10.1002/jha2.445
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：962 / 965
页数：4
相关论文
共 50 条
  • [1] Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations
    Dvorakova, Dana
    Racil, Zdenek
    Jeziskova, Ivana
    Palasek, Ivo
    Protivankova, Marketa
    Lengerova, Martina
    Razga, Filip
    Mayer, Jiri
    AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (12) : 926 - 929
  • [2] Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations
    Mencia-Trinchant, Nuria
    Hu, Yang
    Alas, Maria Antonina
    Ali, Fatima
    Wouters, Bas J.
    Lee, Sangmin
    Ritchie, Ellen K.
    Desai, Pinkal
    Guzman, Monica L.
    Roboz, Gail J.
    Hassane, Duane C.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2017, 19 (04): : 537 - 548
  • [3] A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations
    D Dvorakova
    M Lengerova
    J Pospisilova
    I Palasek
    J Mayer
    Leukemia, 2009, 23 : 793 - 796
  • [4] A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations
    Dvorakova, D.
    Lengerova, M.
    Pospisilova, J.
    Palasek, I.
    Mayer, J.
    LEUKEMIA, 2009, 23 (04) : 793 - 796
  • [5] EVALUATION OF MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA WITH NPM1 MARKER
    Alizadghandforoush, N.
    Nadali, F.
    Rostami, S.
    Chahardouli, B.
    Ghadimi, H.
    Ghasemi, A.
    Alimoghaddam, K.
    Ghavamzadeh, A.
    HAEMATOLOGICA, 2015, 100 : 657 - 658
  • [6] Unified gene expression signature of novel NPM1 exon 5 mutations in acute myeloid leukemia
    Lisi, Veronique
    Blanchard, Eve
    Vladovsky, Michael
    Audemard, Eric
    Ferghaly, Albert
    Lemieux, Sebastien
    Hebert, Josee
    Sauvageau, Guy
    Lavallec, Vincent-Philippe
    BLOOD ADVANCES, 2022, 6 (17) : 5160 - 5164
  • [7] Assessment of Minimal Residual Disease by NGS in Acute Myeloid Leukemia Patients by Monitoring FLT3 and NPM1 Mutations
    Xie, Z.
    Carson, A. R.
    McClain, V.
    Miller, J. E.
    Levis, M.
    Stenzel, T.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2017, 19 (02): : S10 - S10
  • [8] Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations
    Chou, W-C
    Tang, J-L
    Wu, S-J
    Tsay, W.
    Yao, M.
    Huang, S-Y
    Huang, K-C
    Chen, C-Y
    Huang, C-F
    Tien, H-F
    LEUKEMIA, 2007, 21 (05) : 998 - 1004
  • [9] Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations
    W-C Chou
    J-L Tang
    S-J Wu
    W Tsay
    M Yao
    S-Y Huang
    K-C Huang
    C-Y Chen
    C-F Huang
    H-F Tien
    Leukemia, 2007, 21 : 998 - 1004
  • [10] Dactinomycin in acute myeloid leukemia with NPM1 mutations
    Beziat, Guillaume
    Tavitian, Suzanne
    Bertoli, Sarah
    Huguet, Francoise
    Largeaud, Laetitia
    Luquet, Isabelle
    Vergez, Francois
    Rieu, Jean-Baptiste
    Bories, Pierre
    Delabesse, Eric
    Recher, Christian
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 105 (03) : 302 - 307
12345